Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2, 10 (2002).
  MedlineGoogle Scholar
• 2. Jarnagin WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin. Surg. Oncol. 19(2), 156–176 (2000).
  Medline CASGoogle Scholar
• 3. Shaib YH, El-Serag HB, Davila JA, Morgan R, Mcglynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128(3), 620–626 (2005).
  MedlineGoogle Scholar
• 4. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273–1281 (2010).
  Medline CASGoogle Scholar
• 5. Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 7(9), 943–962 (2017). • An overview about precision oncology in biliary tract cancers.
  Medline CASGoogle Scholar
• 6. Lamarca A, Frizziero M, Mcnamara MG, Valle JW. Clinical and translational research challenges in biliary tract cancers. Curr. Med. Chem. doi:10.2174/0929867327666200123090153 (2020) (Epub ahead of print).
  Google Scholar
• 7. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10(2), 116–129 (2010). • A comprehensive review about FGFR signalling in cancer.
  Medline CASGoogle Scholar
• 8. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol. Cancer Res. 8(11), 1439–1452 (2010).
  Medline CASGoogle Scholar
• 9. Murakami M, Simons M. Fibroblast growth factor regulation of neovascularization. Curr. Opin. Hematol. 15(3), 215–220 (2008).
  Medline CASGoogle Scholar
• 10. Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17(5), 318–332 (2017).
  Medline CASGoogle Scholar
• 11. Ross JS, Wang K, Gay L et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19(3), 235–242 (2014).
  Medline CASGoogle Scholar
• 12. Graham RP, Barr Fritcher EG, Pestova E et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol. 45(8), 1630–1638 (2014).
  Medline CASGoogle Scholar
• 13. Nakamura H, Arai Y, Totoki Y et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47(9), 1003–1010 (2015). •• Large molecular characterization of biliary tract cancers.
  Medline CASGoogle Scholar
• 14. Arai Y, Totoki Y, Hosoda F et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59(4), 1427–1434 (2014).
  Medline CASGoogle Scholar
• 15. Javle M, Lowery M, Shroff RT et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J. Clin. Oncol. 36(3), 276–282 (2018).
  Medline CASGoogle Scholar
• 16. Makawita S, Abou-Alfa GK, Roychowdhury S et al. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. doi:10.2217/fon-2020-0299 (2020) (Epub ahead of print).
  Google Scholar
• 17. Hall TG, Yu Y, Eathiraj S et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS ONE 11(9), e0162594 (2016).
  MedlineGoogle Scholar
• 18. Mazzaferro V, El-Rayes BF, Droz Dit Busset M et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br. J. Cancer 120(2), 165–171 (2019).
  Medline CASGoogle Scholar
• 19. Park JO, Feng Y-H, Chen Y-Y et al. Updated results of a Phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J. Clin. Oncol. 37(Suppl. 15), 4117–4117 (2019).
  Google Scholar
• 20. Cleary JM, Voss MH, Meric-Bernstam F et al. Safety and efficacy of the selective FGFR inhibitor debio 1347 in Phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC). J. Clin. Oncol. 36(Suppl. 4), 447–447 (2018).
  Google Scholar
• 21. Chae YK, Hong F, Vaklavas C et al. Phase II Study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W. J. Clin. Oncol. 38(21), 2407–2417 (2020).
  Medline CASGoogle Scholar
• 22. Fauvel B, Yasri A. Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. MAbs 6(4), 838–851 (2014).
  MedlineGoogle Scholar
• 23. Tolcher AW. Antibody drug conjugates: lessons from 20 years of clinical experience. Ann. Oncol. 27(12), 2168–2172 (2016).
  Medline CASGoogle Scholar
• 24. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5(10), 761–772 (2005).
  Medline CASGoogle Scholar
• 25. Acquaviva J, He S, Sang J et al. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Mol. Cancer Res. 12(5), 703–713 (2014).
  Medline CASGoogle Scholar
• 26. Gu TL, Deng X, Huang F et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS ONE 6(1), e15640 (2011).
  Medline CASGoogle Scholar
• 27. Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J. Gastrointestinal Oncol. 10(4), 751–765 (2019).
  MedlineGoogle Scholar
• 28. Battaglin F, Xiu J, Baca Y et al. Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC). J. Clin. Oncol. 38(Suppl. 4), 479–479 (2020).
  Google Scholar
• 29. Doebele RC, Drilon A, Paz-Ares L et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three Phase I-II trials. Lancet Oncol. 21(2), 271–282 (2020).
  Medline CASGoogle Scholar
• 30. Hong DS, Dubois SG, Kummar S et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three Phase I/II clinical trials. Lancet Oncol. 21(4), 531–540 (2020).
  Medline CASGoogle Scholar
• 31. Hyman DM, Puzanov I, Subbiah V et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373(8), 726–736 (2015).
  Medline CASGoogle Scholar
• 32. Wainberg ZA, Lassen UN, Elez E et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial. J. Clin. Oncol. 37(Suppl. 4), 187–187 (2019).
  Google Scholar
• 33. Bekaii-Saab T, Phelps MA, Li X et al. Multi-institutional Phase II study of selumetinib in patients with metastatic biliary cancers. J. Clin. Oncol. 29(17), 2357–2363 (2011).
  Medline CASGoogle Scholar
• 34. Bridgewater J, Lopes A, Beare S et al. A Phase Ib study of Selumetinib in combination with cisplatin and gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer 16, 153 (2016).
  MedlineGoogle Scholar
• 35. Sia D, Hoshida Y, Villanueva A et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144(4), 829–840 (2013).
  Medline CASGoogle Scholar
• 36. Pant S, Saleh M, Bendell J et al. A Phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann. Oncol. 25(7), 1416–1421 (2014).
  Medline CASGoogle Scholar
• 37. Goyal L, Zheng H, Yurgelun MB et al. A Phase II and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 123(11), 1979–1988 (2017).
  Medline CASGoogle Scholar
• 38. Farshidfar F, Zheng S, Gingras MC et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 19(13), 2878–2880 (2017).
  Medline CASGoogle Scholar
• 39. Baghdadi TA, Halabi S, Garrett-Mayer E et al. Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precision Oncol. doi:10.1200/po.19.00124(3), 1–8 (2019) (Epub ahead of print).
  Google Scholar
• 40. Golan T, Raitses-Gurevich M, Kelley RK et al. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist 22(7), 804–810 (2017).
  Medline CASGoogle Scholar
• 41. Galdy S, Lamarca A, Mcnamara MG et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 36(1), 141–157 (2017).
  Medline CASGoogle Scholar
• 42. Le DT, Durham JN, Smith KN et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409–413 (2017).
  Medline CASGoogle Scholar
• 43. Gani F, Nagarajan N, Kim Y et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 23(8), 2610–2617 (2016).
  MedlineGoogle Scholar
• 44. Fontugne J, Augustin J, Pujals A et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 8(15), 24644–24651 (2017).
  MedlineGoogle Scholar
• 45. Marabelle A, Le DT, Ascierto PA et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J. Clin. Oncol. 38(1), 1–10 (2020).
  Medline CASGoogle Scholar
• 46. Liu PCC, Koblish H, Wu L et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2 and 3, displays activity against genetically defined tumor models. PLoS ONE 15(4), e0231877 (2020).
  Medline CASGoogle Scholar
• 47. Saleh M, Gutierrez M, Subbiah V et al. Preliminary results from a Phase I/II study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies. Presented at: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Philadelphia, PA, USA, 26–30 October 2017.
  Google Scholar
• 48. Lamarca A, Palmer DH, Wasan HS et al. ABC-06 | A randomised Phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J. Clin. Oncol. 37(Suppl. 15), 4003–4003 (2019).
  Google Scholar
• 49. Abou-Alfa GK, Sahai V, Hollebecque A et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, Phase II study. Lancet Oncol. 21(5), 671–684 (2020). •• First reporting of the Phase II FIGHT-202 trial showing activity of pemigatinib in FGFR altered advanced cholangiocarcinoma patients.
  Medline CASGoogle Scholar
• 50. Ying J, Chen J. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: a comprehensive meta-analysis of published data. Crit. Rev. Oncol. Hematol. 139, 134–142 (2019).
  MedlineGoogle Scholar
• 51. Lowery MA, Goff LW, Keenan BP et al. Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes. Cancer 125(24), 4426–4434 (2019).
  MedlineGoogle Scholar
• 52. Lamarca A, Ross P, Wasan HS et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02 and -03 clinical trials. J. Natl Cancer Inst. 112(2), 200–210 (2020).
  MedlineGoogle Scholar
• 53. Jain A, Borad MJ, Kelley RK et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precision Oncol. doi:10.1200/po.17.00080(2), 1–12 (2018) (Epub ahead of print).
  MedlineGoogle Scholar
• 54. Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15(1), 51–69 (2016).
  Medline CASGoogle Scholar
• 55. Nti AA, Serrano LW, Sandhu HS et al. Frequent subclinical macular changes in combined BRAF/MEK inhibition with high-dose hydroxychloroquine as treatment for advanced metastatic BRAF mutant melanoma: preliminary results from a Phase I/II clinical treatment trial. Retina 39(3), 502–513 (2019).
  Medline CASGoogle Scholar
• 56. Kim SM, Kim H, Yun MR et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis 5(7), e241 (2016).
  Medline CASGoogle Scholar
• 57. Lee SY, Na YJ, Jeong YA, Kim JL, Oh SC, Lee DH. Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor. Int. J. Biochem. Cell Biol. 102, 128–137 (2018).
  Medline CASGoogle Scholar
• 58. Goyal L, Saha SK, Liu LY et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7(3), 252–263 (2017). •• Identification of mechanisms of acquired resistance to FGFR inhibitors.
  Medline CASGoogle Scholar
• 59. Datta J, Damodaran S, Parks H et al. Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398. Mol. Cancer Ther. 16(4), 614–624 (2017).
  Medline CASGoogle Scholar
• 60. Bockorny B, Rusan M, Chen W et al. RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade. Mol. Cancer Ther. 17(7), 1526–1539 (2018).
  Medline CASGoogle Scholar
• 61. Wang X, Ai J, Liu H et al. The secretome engages STAT3 to favor a cytokine-rich microenvironment in mediating acquired resistance to FGFR inhibitors. Mol. Cancer Ther. 18(3), 667–679 (2019).
  Medline CASGoogle Scholar
• 62. Grygielewicz P, Dymek B, Bujak A et al. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. Gastric Cancer 19(1), 53–62 (2016).
  Medline CASGoogle Scholar
• 63. Kalyukina M, Yosaatmadja Y, Middleditch MJ, Patterson AV, Smaill JB, Squire CJ. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. Chem. Med. Chem. 14(4), 494–500 (2019).
  CASGoogle Scholar